-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Neutral on Amgen, Raises Price Target to $435

Benzinga·11/05/2026 16:04:12
Listen to the news
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $378 to $435.